ONCO Onconetix Inc Total Asset Value of Company

Onconetix, Inc. (ONCO) develops solutions to combat cancer and male health issues, leveraging patent protection for the global rollout of high-margin products. The business remains independent of macroeconomic trends, relying on the sale of tests and therapies in Europe and the US. The market dynamics of total assets reflected in the price action stand at 17.78, supported by the expansion of Entadfi, the development of diagnostic systems, and new B2B deals.

ONCO (Onconetix, Inc.) Company Total Assets history from 02/21/2024 to 10/31/2026

Analytical breakdowns and data insights for company Onconetix Corp (ONCO)

- stock value and consensus price forecast:
Market Price onconetix.gcs-web.com|ONCO - Price Target Chart
- market capitalization data:
Market Valuation Onconetix Corporation|ONCO - Enterprise Value
- issuer book value statistics:
Accounting Value of a Share Onconetix|ONCO - Book Capitalization|Market Capitalization to Book Value Ratio onconetix.gcs-web.com|ONCO - Aggregate Company Assets
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Onconetix, Inc.|ONCO - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Onconetix Corporation|ONCO - Company Aggregate Debts|Debts to Book Capitalization Onconetix Corporation|ONCO - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Onconetix|Interim Coverage Ratio onconetix.gcs-web.com
- net income and valuation multiples indicators:
ONCO - Company Net Income
Fundamental valuation:Onconetix, Inc.

Total assets represent the aggregate volume of business resources, calculated reverse-engineered via ROA to identify the impact of cost inflation on the balance sheet. Analyzing this valuation of total asset value allows for tracking the expansion of the Onconetix, Inc. (ONCO) base, where resource growth is critical for the capitalization of intellectual property and the subsequent global scaling of high-margin oncology therapy drugs.

Key competitors

Company Assets summittxinc.com (SMMT)|Aggregate Company Assets Moderna|Vaxcyte Inc - Total Asset Value of Company|Company Total Assets TARS|CRMD (CorMedix Therapeutics) - Aggregate Asset Value|Company Total Assets MCRB (Seres Therapeutics)|Company Total Assets sperotherapeutics.com SPRO|SCYX - Aggregate Company Assets|Aggregate Asset Value ANTX (AN2 Therapeutics, Inc.)|polypid.com (PYPD) - Aggregate Company Assets|Cumulative Company Assets YS Biopharma Co., Ltd.|ITRM (Iterum Therapeutics PLC) - Company Total Assets|Company Total Assets BiomX Ltd|Cumulative Company Assets SNGX (Soligenix, Inc.)|SXTP (60degreespharma.com) - Aggregate Asset Value|Company Total Assets OGEN (Oragenics)|Company Total Asset Base OpGen Corporation (OPGN)